1SKF401E — Zentiva as Share Price
Last trade - 00:00- €48.61m
- €29.29m
- €113.24m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.43 | ||
| Price to Tang. Book | 0.44 | ||
| Price to Free Cashflow | 1.47 | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2011 | 2012 | 2013 | 2014 | 2015 | 2016E | 2017E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 169.02 | 186.22 | 166.35 | 139.72 | 113.24 | n/a | n/a | -15.12% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +12.09 | +906.33 | -36.43 | -29.87 | -51.28 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Zentiva as is a Slovakia-based company engaged in generic pharmaceuticals business sector. The Company develops, manufactures, and sells generic medicinal products, primarily used in primary care sector. Its portfolio includes preparations for various therapeutic areas, including cardiovascular system, women’s healthcare, respiratory system, antimicrobials, urological system, central nervous system, pain, and gastrointestinal system.
Directors
- Last Annual
- December 31st, 2015
- Last Interim
- June 30th, 2003
- Incorporated
- May 1st, 1992
- Public Since
- May 1st, 2008
- No. of Employees
- 101
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Bratislava Stock Exchange
- Shares in Issue
- 1,620,192
- Address
- Einsteinova 24, BRATISLAVA, 851 01
- Web
- https://www.zentiva.sk/
- Phone
- +421 239183010
- Auditors
- Ernst & Young Slovakia, spol. s r.o.
Similar to 1SKF401E
Biotika as
Bratislava Stock Exchange
FAQ
As of Today at 19:25 UTC, shares in Zentiva as are trading at €220.00. This share price information is delayed by 15 minutes.
Shares in Zentiva as last closed at €220.00 and the price had moved by +19.05% over the past 365 days. In terms of relative price strength the Zentiva as share price has outperformed the FTSE Global All Cap Index by +11.76% over the past year.
There is no consensus recommendation for this security.
Zentiva as does not currently pay a dividend.
Zentiva as does not currently pay a dividend.
Zentiva as does not currently pay a dividend.
To buy shares in Zentiva as you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €220.00, shares in Zentiva as had a market capitalisation of €48.61m.
Here are the trading details for Zentiva as:
- Country of listing: Slovakia
- Exchange: BRA
- Ticker Symbol: 1SKF401E
Based on an overall assessment of its quality, value and momentum Zentiva as is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zentiva as. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -13.01%.
As of the last closing price of €220.00, shares in Zentiva as were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Zentiva as PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €220.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Zentiva as' directors